Vericel Corp
Vericel Corporation (NASDAQ: VCEL) is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The company operates through a highly differentiated portfolio of cell therapy and specialty biologic products that combine innovations in biology with medical technologies. Vericel was… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vericel Corp does
In the company’s own words
Vericel Corporation (NASDAQ: VCEL) is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The company operates through a highly differentiated portfolio of cell therapy and specialty biologic products that combine innovations in biology with medical technologies. Vericel was among the first companies to achieve commercial success in the complex field of cell therapies, utilizing tissue engineering to regenerate skin and healthy knee cartilage.
The company's core product portfolio consists of three FDA-approved offerings. MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic cartilage defects of the knee in adults. In August 2024, the FDA approved a supplemental application expanding MACI's indication to include arthroscopic delivery through small incisions using custom-designed instruments, marketed as MACI Arthro. Epicel is a permanent skin replacement device indicated for treating adult and pediatric patients with deep-dermal or full-thickness burns comprising at least 30 percent of total body surface area. NexoBrid is a topically-administered biological orphan product containing proteolytic enzymes for eschar removal in burn patients, for which Vericel holds exclusive North American rights through a license agreement with MediWound Ltd.
Vericel manufactures MACI and Epicel at its facility in Cambridge, Massachusetts, with a newly completed manufacturing facility in Burlington, Massachusetts designed to eventually become the primary manufacturing location. NexoBrid is manufactured by MediWound, primarily at locations in Israel. The company operates two specialized sales teams: one dedicated to MACI targeting orthopedic surgeons, and a burn care team focused on both Epicel and NexoBrid serving approximately 140 burn centers across the United States.
The company's strategic objectives include expanding MACI growth initiatives, seeking clinical indication expansion for additional joints including the ankle, launching MACI in select international markets such as the United Kingdom, leveraging its burn care portfolio to expand adoption across burn centers, and generating positive operating income and cash flow. In 2025, Vericel initiated the MASCOT trial, a randomized controlled clinical trial evaluating MACI for treating osteochondral lesions of the talus, representing a significant potential expansion of the product's addressable market. More information is available at www.vericel.com.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- BURLINGTON, MA
- Fiscal year end
- December
- CIK
- 887359
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vericel Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vericel Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vericel Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vericel Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vericel Corp's last four quarterly filings that the numbers alone won't show?”